Short Communication

Prevalence and prognostic significance of heart failure with preserved ejection fraction in systemic sclerosis

*Author for correspondence:

E-mail Address: martafontesoliveira@gmail.com

Department of Cardiology, Centro Hospitalar Universitário do Porto, Largo do Prof. Abel Salazar, Porto 4099-001, Portugal

Search for more papers by this author

Ana Leonor Rei

Instituto de Ciências Biomédicas Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, Porto 4050-313, Portugal

Search for more papers by this author

Maria Isilda Oliveira

https://orcid.org/0000-0001-8724-6262

Centre of Physical Activity, Health & Leisure, Faculty of Sport, University of Porto, R. Dr. Plácido da Costa 91, Porto 4200-450, Portugal

Search for more papers by this author

Isabel Almeida

https://orcid.org/0000-0002-8867-1540

Department of Clinical Immunology, Centro Hospitalar Universitário do Porto, Largo do Prof. Abel Salazar, Porto 4099-001, Portugal

Search for more papers by this author

Mário Santos

https://orcid.org/0000-0002-4509-0260

Department of Cardiology, Centro Hospitalar Universitário do Porto, Largo do Prof. Abel Salazar, Porto 4099-001, Portugal

Search for more papers by this author

Published Online:22 Jun 2021https://doi.org/10.2217/fca-2020-0238

View article

Abstract

Aim: Heart failure with preserved ejection fraction (HFpEF) is a clinically relevant complication of systemic sclerosis (SSc). We aimed to examine the prevalence, correlates and prognostic significance of HFpEF in an SSc population. Materials & methods: HFpEF was defined by the presence of exertional dyspnoea, abnormal cardiac structure (left ventricular hypertrophy or left atrial enlargement) and NT-proBN (>125 pg/ml). Results: Of the 155 studied patients, 27% had HFpEF criteria. These patients were older, had more cardiovascular risk factors, and were more likely to have atrial fibrillation or interstitial lung disease. Conclusion: Over a median follow-up of 9 years, SSc patients with HFpEF had a 3.4-fold increased risk of dying (HR: 3.37, 95% CI: 1.21–9.31), although this association has lost statistical significance after adjusting for age. On the contrary, NT-proBNP was an independent predictor of a worse prognosis.

Lay abstract

Heart failure with preserved ejection fraction (HFpEF) is the most common heart failure type worldwide and can be a complication of the rare disease of systemic sclerosis (SSc). In this study, we examined the proportion of SSc patients who presented the diagnostic criteria of HFpEF. Of the 155 studied patients with SSc, one out of four had those HFpEF criteria. These patients were older, had more cardiovascular risk factors, and were more likely to have arrhythmias or lung disease. Over 9 years, SSc patients with HFpEF had a 3.4-fold increased risk of dying, although this association was lost after adjusting for age. NT-proBNP, a heart failure plasma biomarker, was an independent predictor of worse prognosis.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Denton CP, Khanna D. Systemic sclerosis. Lancet 390(10103), 1685–1699 (2017). • Reviews about systemic sclerosis (SSc), its main features and complications.
MedlineGoogle Scholar
2. Sitia S, Atzeni F, Sarzi-Puttini P et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun. Rev. 8(4), 281–286 (2009).
MedlineGoogle Scholar
3. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin. Arthritis Rheum. 44(2), 208–219 (2014).
MedlineGoogle Scholar
4. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 69(10), 1809–1815 (2010).
MedlineGoogle Scholar
5. Bissell L-A, Anderson M, Burgess M et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 56(6), 912–921 (2017). • Consensus best practice pathway of the UK Systemic Sclerosis Study group on the management of cardiac disease in systemic sclerosis.
MedlineGoogle Scholar
6. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 45(Suppl. 4), iv14–iv17 (2006).
MedlineGoogle Scholar
7. Bissell L-A, Md Yusof MY, Buch MH. Primary myocardial disease in scleroderma - a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. Rheumatology (Oxford) 56(6), 882–895 (2017).
MedlineGoogle Scholar
8. Tennøe AH, Murbræch K, Andreassen JC et al. Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. J. Am. Coll. Cardiol. 72(15), 1804–1813 (2018). •• Original paper in which diastolic dysfunction was assessed in a large cohort of patients with systemic sclerosis (SSc; n = 275), suggesting that diastolic dysfunction predicts mortality in patients with SSc.
MedlineGoogle Scholar
9. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65(11), 2737–2747 (2013). •• Official classification criteria for SSc by the American College of Rheumatology/European League against Rheumatism.
MedlineGoogle Scholar
10. Avouac J, Fransen J, Walker UA et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann. Rheum. Dis. 70(3), 476–481 (2011).
Medline CASGoogle Scholar
11. Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28(1), 1–39.e14 (2015).
MedlineGoogle Scholar
12. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18(8), 891–975 (2016). •• European Society of Cardiology Guidelines for the diagnosis and treatment chronic heart failure.
MedlineGoogle Scholar
13. Hoffmann-Vold A-M, Maher TM, Philpot EE et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2(2), e71–e83 (2020).
Google Scholar
14. Gerber Y, Weston SA, Redfield MM et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med. 175(6), 996–1004 (2015).
MedlineGoogle Scholar
15. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355(3), 251–259 (2006).
Medline CASGoogle Scholar
16. Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 10(3), 377–388 (2014).
MedlineGoogle Scholar
17. Ceia F, Fonseca C, Mota T et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 4(4), 531–539 (2002).
MedlineGoogle Scholar
18. Desai CS, Lee DC, Shah SJ. Systemic sclerosis and the heart: current diagnosis and management. Curr. Opin. Rheumatol. 23(6), 545–554 (2011).
MedlineGoogle Scholar
19. Parks JL, Taylor MH, Parks LP, Silver RM. Systemic sclerosis and the heart. Rheum. Dis. Clin. North Am. 40(1), 87–102 (2014).
MedlineGoogle Scholar
20. Bellando-Randone S, Lepri G, Huscher D. Predictors to develop definite systemic sclerosis (SSc): results from an International Multicentre Study on very early diagnosis of systemic sclerosis (VEDOSS). ACR meeting abstracts. https://acrabstracts.org/abstract/predictors-to-develop-definite-systemic-sclerosis-ssc-results-from-an-international-multicentre-study-on-very-early-diagnosis-of-systemic-sclerosis-vedoss/
Google Scholar
21. Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin. Exp. Rheumatol. 30(71 Suppl. 2), S30–S37 (2012).
MedlineGoogle Scholar
22. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol. 33(7), 1948–1955 (1999).
Medline CASGoogle Scholar
23. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128(10), 1085–1093 (2013).
MedlineGoogle Scholar
24. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118(1), 2–10 (2005). • Meta-analysis of individual patient data on causes of mortality in SSc.
MedlineGoogle Scholar
25. Lefèvre G, Dauchet L, Hachulla E et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 65(9), 2412–2423 (2013).
MedlineGoogle Scholar
26. Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 54(9), 3043–3050 (2006).
MedlineGoogle Scholar
27. Bourji KI, Kelemen BW, Mathai SC et al. Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. Pulm. Circ. 7(2), 409–420 (2017).
MedlineGoogle Scholar

Vol. 18, No. 1

Supplemental Materials

Metrics

Downloaded 149 times

History

Received 24 December 2020

Accepted 7 June 2021

Published online 22 June 2021

Published in print January 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fca-2020-0238

Author contributions

M Santos and I Almeida contributed to the conception of the study. MF Oliveira and AL Rei contributed to data collection. M Santos and MF Oliveira participated in statistical analysis. M Santos, MF Oliveira, AL Rei and MI Oliveira drafted the manuscript. All authors critically revised the manuscript, gave final approval and agreed to be accountable for all aspects of the work.

Financial & competing interests disclosure

This project was supported by Fundação para a Ciência e Tecnologia grant (PTDC/MEC-CAR/30011/2017), co-financed by the FEDER – Fundo Europeu de Desenvolvimento Regional under the new Partnership Agreement PT2020 within the project POCI-01-0145-FEDER-030011. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download